LncRNA CTBP1-AS2 regulates miR-216a/PTEN to suppress ovarian cancer cell proliferation

被引：23

作者：

Cui, Kaiying ^{[1
]}

Zhu, Genhai ^{[1
]}

机构：

[1] Hainan Peoples Hosp, Dept Gynaecol, Haikou 570311, Hainan, Peoples R China

来源：

JOURNAL OF OVARIAN RESEARCH | 2020年 / 13卷 / 01期

关键词：

CTBP1-AS2; Ovarian cancer; miR-216a; PTEN; Proliferation; EPITHELIAL-MESENCHYMAL TRANSITION; LONG NONCODING RNAS; TARGETED THERAPY; METASTASIS; DIAGNOSIS; RISK;

D O I：

10.1186/s13048-020-00689-6

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background We analyzed TCGA dataset and observed the downregulation of CTBP1-AS2 in ovarian cancer (OC), while the function of CTBP1-AS2 has only been investigated in diabetes and cardiomyocyte hypertrophy, but not in cancer biology. We therefore analyzed the involvement of CTBP1-AS2 in OC. Result We found that CTBP1-AS2 was downregulated in OC and predicted poor survival. CTBP1-AS2 in luciferase activity assay interacted with miR-216a, while overexpression of CTBP1-AS2 and miR-216a had no significant effects on the expression of each other. However, increased expression level of PTEN, a target of miR-216a, was observed after CTBP1-AS2 overexpression. Increased proliferation rate of OC cells was observed after the overexpression of miR-216a. CTBP1-AS2 and PTEN overexpression resulted in the reduced proliferation rate of OC cells and reduced effects of miR-216a overexpression. Conclusion CTBP1-AS2 regulates miR-216a/PTEN to suppress OC cell proliferation.

引用

页数：6

共 17 条

[11] MicroRNA-216a promotes the metastasis and epithelial-mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway [J].

Liu, Haizhi ;

Pan, Ying ;

Han, Xiaoxue ;

Liu, Jia ;

Li, Ruiman .

ONCOTARGETS AND THERAPY, 2017, 10 :2701-2709

[12] Sp1-induced LncRNA CTBP1-AS2 is a novel regulator in cardiomyocyte hypertrophy by interacting with FUS to stabilize TLR4 [J].

Luo, Xiaojia ;

He, Sen ;

Hu, Yongmei ;

Liu, Jianxiong ;

Chen, Xiaoping .

CARDIOVASCULAR PATHOLOGY, 2019, 42 :21-29

[13] Clinical significance of long noncoding RNA VIM-AS1 and CTBP1-AS2 expression in type 2 diabetes [J].

Omidvar, Maryam Erfanian ;

Ghaedi, Hamid ;

Kazerouni, Faranak ;

Kalbasi, Saeid ;

Shanaki, Mehrnoosh ;

Miraalamy, Ghasem ;

Zare, Ali ;

Rahimipour, Ali .

JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (06) :9315-9323

[14] Precision targeted therapy of ovarian cancer [J].

Sapiezynski, Justin ;

Taratula, Oleh ;

Rodriguez-Rodriguez, Lorna ;

Minko, Tamara .

JOURNAL OF CONTROLLED RELEASE, 2016, 243 :250-268

[15] Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].

Sung, Hyuna ;

Ferlay, Jacques ;

Siegel, Rebecca L. ;

Laversanne, Mathieu ;

Soerjomataram, Isabelle ;

Jemal, Ahmedin ;

Bray, Freddie .

CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) :209-249

[16] Targeted therapy for ovarian cancer: the rapidly evolving landscape of PARP inhibitor use [J].

Walsh, Christine .

MINERVA GINECOLOGICA, 2018, 70 (02) :150-170

[17] MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer [J].

Xia, Hongping ;

Ooi, London Lucien P. J. ;

Hui, Kam M. .

HEPATOLOGY, 2013, 58 (02) :629-641

← 1 2 →